Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04839549
Other study ID # The ROSE Study
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date June 6, 2020
Est. completion date November 29, 2022

Study information

Verified date June 2023
Source Eye Associates of Central Texas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine patient preference and treatment outcomes with an intracanalicular dexamethasone (0.4mg) insert compared to a standard steroid drop regimen in the contralateral eye for the treatment of ocular rosacea.


Description:

Prospective Open-label Interventional Study Randomized, self-controlled design in which one eye receives Dextenza (Group A) intracanalicular insert and the contralateral eye receives topical fluorometholone 0.1% BID (Group B) for 2 weeks then once daily for 2 weeks for the treatment of ocular rosacea. All patients will be placed on oral doxycycline 100mg BID for one month and tapered to a maintenance dose of 100mg once daily for the remainder of the study. Patient evaluations will be performed at Screening/Baseline, Insertion Day, Month 1 and Month 2.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 29, 2022
Est. primary completion date November 29, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be at least 18 years of age, any gender or race - Provide written informed consent - Sign the HIPAA form - Attend all study visits - Take all study medications as directed - Be willing to avoid all disallowed medications - Be willing to avoid all contact lens wear between Dextenza insertion (Visit 2) and Post-op 1 month visit (Visit 3) - Have a best-corrected visual acuity (BCVA) or greater than or equal to 50 ETDRS letters (20/100 Snellen equivalent) or better in each eye at the screening visit. - For women of childbearing age (menarche to less than 12 months of menopause who have not undergone surgical sterilization), be willing to have a urine pregnancy test and agree to use a medically acceptable form of birth control throughout the study duration. - Have a documented diagnosis of Ocular Rosacea and exhibit typical signs or symptoms associated with the diagnosis (irritation, burning, foreign body sensation, redness, itching, inflammation, dry eye, discharge) Exclusion Criteria: - Have any allergy or other historical contraindication to the medications in the protocol - Is unable to use the study medications regularly as directed - Have any other ocular disease that could affect the subject's ability to participate in the study safely (narrow angle glaucoma, iritis, current infection, elevated intraocular pressure, history of significant steroid response with and IOP >22mmHg, punctal size less than 0.4mm or lid malformation that would preclude insertion of the Dextenza insert) - Have known history of herpetic eye disease (either active or historical) - Have a history of refractive surgery within the past 2 years - Have a history of retinal detachment, diabetic retinopathy, or active retinal disease - Is currently (within the past 7 days) using an ophthalmic steroid preparation (drop, ointment or insert form) - Is currently using ocular, topical, or systemic non-steroidal anti-inflammatory drugs (NSAIDs) - Baby aspirin (81mg) is allowed as long as a stable dose has been maintained for at least 30 days prior to Dextenza insertion and will continue to be maintained for the duration of the study - Have an active infectious disease or is currently taking (or has taken within 7 days of initiation into the study) oral antibiotics - Is actively being treated with local or systemic immunosuppression, including systemic steroids - Have a planned ocular or systemic surgery within 30 days of the placement of the Dextenza insert. - Have used a study drug or participated in a clinical study within 30 days of the beginning of this study - Is currently pregnant, planning to become pregnant, or breastfeeding - Is an employee or direct family member of an employee at the clinic site - Have a diagnosis of any significant uncontrolled illness - Have a history of alcohol or drug abuse in the past year - Is a current smoker - Have used an investigational drug or medical device within 30 days of the study or be concurrently enrolled in another investigational product trial - Have an intraocular pressure that is less than 5mmHg or greater than 22mmHg or any type of glaucoma - Is deemed unsafe for the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dextenza 0.4Mg Ophthalmic Insert
Dextenza 0.4Mg Ophthalmic Insert
Fluoromethalone .01%
Fluoromethalone .01%

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Eye Associates of Central Texas

Outcome

Type Measure Description Time frame Safety issue
Primary Change in OSDI As measured by OSDI questionnaire Accessed at all time points (Day -30 - day -1, week 4, week 8)
Primary Patient preference in treatment therapy As measured by Adapted COMTOL questionnaire Accessed at Week 4
Secondary Change in tear breakup time As measured by Fluoroscein (Bioglo strip moistened with saline) placed in the inferior fornix of each eye. A cobalt blue light beam will be used to count the number of seconds between the last blink and the appearance of a dry spot or break in tear film. Accessed at all time points (Day -30 - day -1, week 4, week 8)
Secondary Change in Expression of Gland Scale As measured by digitally compressing the lower and upper lids and quantified on a 4-point scale:
(0- all five glands, 1 - three to four glands, 2 - one to two glands, 3 - zero glands).
The values will be averaged for each eye.
Accessed at all time points (Day -30 - day -1, week 4, week 8)
Secondary Change in corneal staining As measured by the NEI/Industry Grading system Accessed at all time points (Day -30 - day -1, week 4, week 8)
See also
  Status Clinical Trial Phase
Completed NCT02066051 - IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD N/A
Completed NCT03655197 - Lipidome and Microbiome Profile of the Eye in Rosacea Early Phase 1
Recruiting NCT06466018 - Research Into Diagnostic and Prognostic Molecular and Imaging Biomarkers of Ocular Disorders Associated With Neurovascular Deregulation: Biocor Cohort N/A
Recruiting NCT05296837 - Ocular Rosacea Biome Study Phase 4
Not yet recruiting NCT04025801 - Heidelberg In Vivo Confocal Microscopy to Evaluate the Ocular Surface Disorders of Healthy and Diseased Individuals
Completed NCT03194698 - Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea N/A
Completed NCT03479853 - Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE